New drug aims to ease harsh recovery for older cancer patients
NCT ID NCT03315026
Summary
This study is testing if a drug called siltuximab can reduce the severe fatigue, pain, and nausea that often follow a stem cell transplant. It focuses on patients aged 60-75 with multiple myeloma or AL amyloidosis. The goal is to block a specific protein linked to inflammation, aiming to improve recovery and quality of life right after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.